DOP2003000669A - Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos - Google Patents
Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicosInfo
- Publication number
- DOP2003000669A DOP2003000669A DO2003000669A DO2003000669A DOP2003000669A DO P2003000669 A DOP2003000669 A DO P2003000669A DO 2003000669 A DO2003000669 A DO 2003000669A DO 2003000669 A DO2003000669 A DO 2003000669A DO P2003000669 A DOP2003000669 A DO P2003000669A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- vpac2
- peptides
- hypofisary
- cyclass
- adelinate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Esta invención provee nuevos peptidos que funcionan in vivo como agonistas del receptor VPAC2. Se demuestra que estos polipéptidos secretagogos de la insulina reducen mas la glucosa sanguinea in vivo que los controles luego de la provocación con glucosa. Los polipéptidos de esta invención también son estables en la formulación y tienen vidas medias prolongadas. Los péptidos de la presente invención proveen una nueva terapia para pacientes con secreción reducida de insulina endógena, en particular los diabeticos del tipo 2. En particular, la invención es un polipéptido seleccionado de un grupo especifico de polipéptidos relacionados con VPAC2, o sus equivalentes funcionales. La invencibn se refiere, ademas, a un método de tratamiento de una enfermedad metabólica en un mamifero que comprende administrar una cantidad terapéuticamente efectiva de los péptidos secretagogos de la insulina a dicho mamifero. Se describen, ademas, metodos para preparar los peptidos, tanto recombinantes como sintéticos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39573802P | 2002-07-12 | 2002-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2003000669A true DOP2003000669A (es) | 2004-01-31 |
Family
ID=30115918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2003000669A DOP2003000669A (es) | 2002-07-12 | 2003-07-11 | Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos |
Country Status (20)
Country | Link |
---|---|
US (2) | US7378494B2 (es) |
EP (1) | EP1578358A2 (es) |
JP (1) | JP2006506969A (es) |
CN (1) | CN101405298A (es) |
AR (1) | AR040548A1 (es) |
AU (1) | AU2003267990A1 (es) |
BR (1) | BR0312621A (es) |
CA (1) | CA2491279A1 (es) |
DO (1) | DOP2003000669A (es) |
GT (1) | GT200300142A (es) |
HN (1) | HN2003000217A (es) |
IL (1) | IL165499A (es) |
MX (1) | MXPA04012305A (es) |
PE (1) | PE20040677A1 (es) |
PL (1) | PL377025A1 (es) |
RU (1) | RU2360922C2 (es) |
TW (1) | TW200409641A (es) |
UY (1) | UY27893A1 (es) |
WO (1) | WO2004006839A2 (es) |
ZA (1) | ZA200501118B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301431D0 (sv) * | 2003-05-19 | 2003-05-19 | Dermagen | Novel antimicrobial peptides |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
BRPI0507177A (pt) * | 2004-01-27 | 2007-06-26 | Bayer Pharmaceuticals Corp | agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso |
DE602005005476T2 (de) * | 2004-05-21 | 2009-03-05 | Eli Lilly And Co., Indianapolis | Selektive peptidische agonisten des vpac2-rezeptors |
ATE412010T1 (de) * | 2004-05-21 | 2008-11-15 | Lilly Co Eli | Selektive peptidische agonisten des vpac2- rezeptors |
CA3090413C (en) | 2004-06-04 | 2023-10-10 | Abbott Diabetes Care Inc. | Glucose monitoring and graphical representations in a data management system |
CN101001639A (zh) * | 2004-06-12 | 2007-07-18 | 拜尔药品公司 | 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法 |
US20080085860A1 (en) * | 2004-08-18 | 2008-04-10 | Eli Lilly And Company | Selective Vpac2 Receptor Peptide Agonists |
WO2006023359A2 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
WO2006042152A2 (en) | 2004-10-08 | 2006-04-20 | Forbes Medi-Tech (Research) Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
US7595294B2 (en) | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
US20090170775A1 (en) * | 2004-10-08 | 2009-07-02 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide compositions |
US20070293429A1 (en) * | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
US20080214440A1 (en) * | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
US20060159737A1 (en) * | 2004-11-19 | 2006-07-20 | Steffen Panzner | Pharmaceutical compositions for local administration |
DE602005014672D1 (de) * | 2004-12-21 | 2009-07-09 | Lubrizol Ltd | Zusammensetzungen |
ES2365410T3 (es) * | 2005-04-08 | 2011-10-04 | Amylin Pharmaceuticals, Inc. | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. |
EP1896048A4 (en) * | 2005-05-06 | 2010-11-03 | Bayer Pharmaceuticals Corp | PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE |
US20080194482A1 (en) * | 2005-08-11 | 2008-08-14 | Jorge Alsina-Fernandez | Selective Apac2 Receptor Peptide Agonists |
EP1942941A1 (en) * | 2005-10-26 | 2008-07-16 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
AU2007220775A1 (en) * | 2006-02-28 | 2007-09-07 | Eli Lilly And Company | Selective VPAC2 receptor peptide agonists |
EP2011506A1 (en) * | 2007-07-05 | 2009-01-07 | Nestec S.A. | Supplementation of maternal diet |
WO2010021752A1 (en) * | 2008-08-21 | 2010-02-25 | Alvine Pharmaceuticals, Inc. | Formulation for oral administration of proteins |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
EP3177309A4 (en) * | 2014-08-06 | 2018-08-15 | Vascular Biosciences | Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same |
WO2016168760A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
WO2017181031A2 (en) | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6972319B1 (en) * | 1999-09-28 | 2005-12-06 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use |
-
2003
- 2003-07-11 RU RU2005103396/13A patent/RU2360922C2/ru not_active IP Right Cessation
- 2003-07-11 PL PL377025A patent/PL377025A1/pl unknown
- 2003-07-11 TW TW092118986A patent/TW200409641A/zh unknown
- 2003-07-11 DO DO2003000669A patent/DOP2003000669A/es unknown
- 2003-07-11 GT GT200300142A patent/GT200300142A/es unknown
- 2003-07-11 CN CNA038166445A patent/CN101405298A/zh active Pending
- 2003-07-11 HN HN2003000217A patent/HN2003000217A/es unknown
- 2003-07-11 UY UY27893A patent/UY27893A1/es not_active Application Discontinuation
- 2003-07-11 AU AU2003267990A patent/AU2003267990A1/en not_active Abandoned
- 2003-07-11 BR BR0312621-8A patent/BR0312621A/pt not_active IP Right Cessation
- 2003-07-11 CA CA002491279A patent/CA2491279A1/en not_active Abandoned
- 2003-07-11 WO PCT/US2003/021761 patent/WO2004006839A2/en active Application Filing
- 2003-07-11 AR AR20030102511A patent/AR040548A1/es unknown
- 2003-07-11 JP JP2004521702A patent/JP2006506969A/ja active Pending
- 2003-07-11 MX MXPA04012305A patent/MXPA04012305A/es unknown
- 2003-07-11 PE PE2003000697A patent/PE20040677A1/es not_active Application Discontinuation
- 2003-07-11 US US10/618,126 patent/US7378494B2/en not_active Expired - Fee Related
- 2003-07-11 EP EP03748938A patent/EP1578358A2/en not_active Withdrawn
-
2004
- 2004-12-01 IL IL165499A patent/IL165499A/en not_active IP Right Cessation
-
2005
- 2005-02-08 ZA ZA200501118A patent/ZA200501118B/en unknown
-
2008
- 2008-05-23 US US12/154,468 patent/US20090258826A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090258826A1 (en) | 2009-10-15 |
EP1578358A2 (en) | 2005-09-28 |
WO2004006839A2 (en) | 2004-01-22 |
GT200300142A (es) | 2004-03-17 |
RU2360922C2 (ru) | 2009-07-10 |
PE20040677A1 (es) | 2004-10-29 |
ZA200501118B (en) | 2006-08-30 |
BR0312621A (pt) | 2005-12-06 |
US20040058870A1 (en) | 2004-03-25 |
MXPA04012305A (es) | 2005-02-25 |
IL165499A (en) | 2010-12-30 |
US7378494B2 (en) | 2008-05-27 |
RU2005103396A (ru) | 2005-09-20 |
JP2006506969A (ja) | 2006-03-02 |
AU2003267990A1 (en) | 2004-02-02 |
HN2003000217A (es) | 2004-07-26 |
UY27893A1 (es) | 2003-12-31 |
CN101405298A (zh) | 2009-04-08 |
TW200409641A (en) | 2004-06-16 |
PL377025A1 (pl) | 2006-01-23 |
AR040548A1 (es) | 2005-04-13 |
CA2491279A1 (en) | 2004-01-22 |
IL165499A0 (en) | 2006-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2003000669A (es) | Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos | |
DOP2000000071A (es) | Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacológico | |
JP6229038B2 (ja) | 修飾された血管作動性腸管ペプチド | |
ES2930750T3 (es) | Composición farmacéutica para tratar un síndrome metabólico | |
US20090202497A1 (en) | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes | |
JP6612251B2 (ja) | エキセンジン−4に由来するペプチド二重glp−1/グルカゴン受容体アゴニスト | |
DE69531889D1 (de) | Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides | |
US8222217B2 (en) | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders | |
AR061203A1 (es) | Moduladores del receptor glp-1 modificados en la terminal n | |
TW200611704A (en) | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | |
ECSP066793A (es) | ||
US20070004619A1 (en) | Relaxin superfamily peptide analogues | |
US8318664B2 (en) | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity | |
TW200716156A (en) | Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use | |
ES2635691T3 (es) | Uso de relaxina para aumentar la distensibilidad arterial | |
RU2673179C2 (ru) | Производное инсулинотропного пептида с модифицированным N-концевым зарядом | |
ECSP003683A (es) | Agonistas del receptor 3(r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico | |
AR025902A1 (es) | Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico | |
TH84721A (th) | อะโกนิสต์ของตัวรับ (vpac2) ของเปปไตด์ที่กระตุ้นปิตูอิตารี่อะดีนิเลตไซเดลส (pacap) และการใช้วิธีการทางเภสัชวิทยาของมัน | |
TH84721B (th) | อะโกนิสต์ของตัวรับ (vpac2) ของเปปไตด์ที่กระตุ้นปิตูอิตารี่อะดีนิเลตไซเดลส (pacap) และการใช้วิธีการทางเภสัชวิทยาของมัน | |
TH87281A (th) | N-เทอร์มินัลลี มอดิไฟด์ glp-1 รีเซปเตอร์ มอดูเลเตอร์ |